TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03530514
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-matching REGN4461
Study: NCT02153840
Drug: PSORI-CM01（YXBCM01） granule
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02153840
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02455908
Drug: Proleukin®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01455649
Drug: calcineurin inhibitor
Normalized name: Calcineurin inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group will maintain their initial immunosuppression therapy with calcineurin inhibitor
Study: NCT00560833
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02359721
Drug: tablet clarithromycin 500 mg (Clarino-500) orally
Normalized name: clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: orally
Study: NCT03431168
Drug: Azithromycin/TMPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tabs po daily x 3 days at enrollment and at each monthly follow up visit
Study: NCT03431168
Drug: Placebo/TMPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tabs po daily x 3 days at enrollment and at each monthly follow up visit
Study: NCT03861000
Drug: [C-11]T-1650
Approvals — FDA: no, EMA: no, PMDA: no
Description: radio-labeled drug
Study: NCT03861000
Drug: BPN14770
Approvals — FDA: no, EMA: no, PMDA: no
Description: selective compound
Study: NCT02140125
Drug: ASP2408
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous administration
Study: NCT02140125
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous administration
Study: NCT01123889
Drug: corticosteroid injection
Normalized name: CORTICOSTEROIDS
DrugBank: Corticosterone (DB04652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Under sterile conditions, patients will receive a 5cc injection consisting of 2cc 1% lidocaine, 2cc 0.5% ropivacaine, and 1cc kenalog corticosteroid (40mg/cc) into the subacromial space utilizing a posterior lateral approach. Patients will be observed for 10 min in clinic for any adverse reactions.
Study: NCT01817257
Drug: Low Molecular Weight Heparin (LMWH)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomised to Arm A will have already received LMWH (Fragmin®), tinzaparin (Innohep®) or enoxaparin (Clexane®) at treatment dose for six months off trial, and should continue the same drug at the same dose for a further six months on trial. No dose alterations are required unless clinically indicated.
Study: NCT03808155
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo ist taken once a day per os five days prior to the operation and two days after the operation.
Study: NCT06556108
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Part of the non-myeloablative lymphocyte-depleting preparative regimen.
Study: NCT00525252
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be orally administered for 12 consecutive weeks
Study: NCT00997074
Drug: ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The most common side effect observed during medical abortion using mifepristone together with misoprostol is abdominal pain. The use of ibuprofen was not shown to interfere with the action of misoprostol to induce uterine contractions and pregnancy expulsion.
Study: NCT01128985
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching canagliflozin placebo once daily for 7 consecutive days from Day 1 to Day 7
Study: NCT00188188
Drug: quinipril
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06190483
Drug: Ascorbic Acid 50 Mg Oral Tablet
Normalized name: ascorbic acid 50 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose given orally (opaque capsule) 60 minutes prior to MRI scan
Study: NCT02884635
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate will be orally administered at stable dose from at least 28 days prior to screening through the screening and treatment periods until the end of the follow-up period.
Study: NCT06417515
Drug: Xiao-Yao-San
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who received Xiao-Yao-San 9 g/day (Kaiser Pharmaceutical Co. Ltd.) were selected for the Xiao-Yao-San group by traditional Chinese doctor with 8 years of experience.
Study: NCT00000257
Drug: 0% N2O and 10% N2O
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00000257
Drug: 0% N2O and 20% N2O
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00000257
Drug: 0% N2O and 30% N2O
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00000257
Drug: 0% N2O and 40% N2O
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01640301
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03077282
Drug: Prasaprohyai
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasaprohyai 95% ethanolic extract capsules will take three times a day before meals
Study: NCT04073550
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib blank analog capsule.
Study: NCT02926690
Drug: OTS167PO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single arm, no competitor
Study: NCT00332904
Drug: spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablet 200 mg pr. day in 3 weeks, evt. dose adjustment
Study: NCT01625806
Drug: RO4602522
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose
Study: NCT00719199
Drug: IMO-2055
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC weekly injections
Study: NCT00719199
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given day 1 of each cycle
Study: NCT00929240
Drug: capecitabine [Xeloda]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg/m2 po bid on days 1-14 of each 3 week cycle (maintenance phase)
Study: NCT02209506
Drug: MLN3126
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLN3126 tablets
Study: NCT02209506
Drug: MLN3126 Matched Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLN3126 placebo-matching tablets
Study: NCT00435084
Drug: APO866
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02469129
Drug: [18F]FluorThanatrace
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the Dosimetry Studies, 10 mCi of \[18F\]FTT will be injected intravenously, and participants will be placed in the following groups to be imaged with PET at the specified time points: 0 minute group--image at 0 and 120 min. after tracer injection; 30 minute group--image at 30 and 150 min. after tracer injection; 60 minute group--image at 60 and 180 min. after tracer injection; and 90 minute group--image at 90 and 210 min. after tracer injection.~For the Kinetic Studies, 10 mCi of \[18F\]FTT will be injected intravenously, and a 60-minute dynamic PET scan will be obtained starting at the time of injection.
Study: NCT00416533
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00332787
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03634982
Drug: RMC-4630
Approvals — FDA: no, EMA: no, PMDA: no
Description: RMC-4630 for oral administration
Study: NCT02413658
Drug: Phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical use of phenytoin solution on dressings of split thickness skin graft sites.
Study: NCT00584974
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01644877
Drug: DAS181 dry powder, formulation F02
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01644877
Drug: Lactose Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04469491
Drug: inhaled type I interferon
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: The interventional arm includes inhaled interferon (9.6 MUI x2/d for 48 hours, then 9.6 MUI x1/d for 8 to 16 days or discharge), in addition to standard care. In phase B, maximum treatment duration is 8 days.
Study: NCT02934607
Drug: Symbicort pMDI with spacer device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relative bioavailability of budesonide and formoterol delivered via Symbicort pressurized metered-dose inhaler (pMDI) with a spacer device (test)
Study: NCT02934607
Drug: Symbicort pMDI without spacer device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relative bioavailability of budesonide and formoterol delivered via Symbicort pMDI without a spacer device (reference)
Study: NCT00454233
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01870635
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible children will receive one dose of an oral disintegrating Placebo (sugar pill) tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.
Study: NCT04576312
Drug: UNI911 inhalation 1% and intranasal spray 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niclosamide is a broad spectrum, host tageting antiviral that inhibits viral replication (by neutralizing endosomal pH) and increases viral clearance (by increasing the autophagic flux). The niclosamide 1% solution is administered as inhalation by nebulization and intranasal by a nasal spray.
Study: NCT04576312
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo formulation contains the vehicle. The solution is administered in the same way as the active drug. Placebo was only administered for cohorts 1-5.
Study: NCT01146925
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 placebo tablets will be given every 12 hours for a total of 8 days, beginning 1-3 hours prior to angiography
Study: NCT04567784
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a harmless, inactive solution to compare and validate the results of the other arms of the study
Study: NCT01850849
Drug: LEO 39652 cream
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01457846
Drug: AZD4547
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets taken, oral, twice daily, commencing with a 2 week on AZD4547, 1 week off AZD4547 schedule.
Study: NCT02853500
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication used in cancer chemotherapy, including intraarterial delivery for liver malignancies.
Study: NCT03100149
Drug: RO7046015
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7046015 will be administered at dose of 4500 milligrams (mg) for participants with body-weight greater than or equal to (\>/=) 65 kilograms (kg) or 3500 mg for participants with body-weight less than (\<) 65 kg.
Study: NCT03100149
Drug: RO7046015
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7046015 will be administered at dose of 1500 mg to all participants in the indicated arm.
Study: NCT03100149
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7046015 placebo will be administered to all participants in the indicated arm.
Study: NCT01993979
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03133767
Drug: Normal Saline 0.9% Infusion Solution Bag
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 liters of intravenous normal saline solution will be administered by peripheral IV
Study: NCT00553995
Drug: salsalate
Normalized name: Salsalate
DrugBank: Salsalate (DB01399)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salsalate 3-4 grams per day as tolerated for nine days
Study: NCT00553995
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01543321
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with placebo consists in:~* 5-week titration to a maximum dose of 200 mg / day~* 5 weeks at stable dose~* 2 weeks in wash-out~The treatment will be blinded for patients and investigators
Study: NCT02380131
Drug: Oxaliplatin plus Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A cycle: Oxaliplatin 130 mg/m2 D1 q3wk.E Capecitabine 2000mg/m2 D1-D14 q3wk、valuation for every two cycles.
Study: NCT01349348
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet, 7.5/15mg , Qd, 7days.
Study: NCT02344810
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02344810
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01768013
Drug: LEO 90105
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once daily for four weeks
Study: NCT02711553
Drug: Placebo Oral
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02711553
Drug: Placebo IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT01337401
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30mg, once daily, oral until 24 weeks or disease progression if sooner
Study: NCT01364987
Drug: ASP015K
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT02094599
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo provided in capsules or as an oral solution in syringes.
Study: NCT00853983
Drug: [14C] AZD0530
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution, Oral, once
Study: NCT01629849
Drug: Placebo to BI 1021958 qd
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet
Study: NCT01629849
Drug: Placebo to BI 1021958 bid
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets
Study: NCT00836940
Drug: GRC 8200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, 25 to 100mg, once/ twice a day, 12 weeks
Study: NCT03767569
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic Acid daily
Study: NCT00003789
Drug: isolated limb perfusion
Normalized name: ISOLATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undergo isolated limb perfusion
Study: NCT01363843
Drug: FOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX6
Study: NCT02520479
Drug: P-CHOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two cycles of P-CHOP:cyclophosphamide, 750 mg/m2 day 1; vincristine,(maximal dose 2 mg),adriamycin , 50 mg/m2 day 1; dexamethasone,10mg days 1-8; Pegaspargase, 2500IU/m2 day 1 are given before radiotherapy
Study: NCT02520479
Drug: P-CHOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two consolidation cycles of P-CHOP are given after radiotherapy
Study: NCT01525758
Drug: SI000413
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 Tablet = 200mg, (400mg, 600mg or 800mg vs. placebo) for 8weeks
Study: NCT03545464
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of cortancyl Oral Tablet 20mg
Study: NCT03649009
Drug: Thiamine
Normalized name: Thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV Thiamine 200 mg diluted in 50 mls normal saline infused over 1 hour 3 times per day for total 3 days after recruitment and randomization
Study: NCT03649009
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: If patient develop redness or rashes after normal saline infusion, IV hydrocortisone 200 mg stat will be given
Study: NCT01656239
Drug: Placebo ( sugar pill)
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01999829
Drug: citrate of caffeine
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01999829
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04152759
Drug: Drug: BAT2506 injection Other Names: Simponi(EU-licensed)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: BAT2506 injection Each subject will receive single subcutaneous injection of 50 mg BAT2506 Injection or Simponi(EU-licensed).~Other Names:~Simponi(EU-licensed)
Study: NCT03153852
Drug: Modified Jessner's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Jessner's solution will be applied on the right side until frosting
Study: NCT03153852
Drug: Trichloroacetic acid
Normalized name: Trichloroacetic Acid
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trichloroacetic acid 20% will be applied in one uniform coat to both sides of the face until frosting
Study: NCT00450216
Drug: Ibuprofen/famotidine
Normalized name: ibuprofen/famotidine 800 mg-26.6 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: HZT-501: Ibuprofen800mg/famotidine 26.6mg administered orally 3 times daily for 24 weeks
Study: NCT00450216
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 800mg administered orally 3 times daily for 24 weeks
Study: NCT03119766
Drug: Kolofort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT03119766
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT04193774
Drug: Oxybuprocaine Hydrochloride 0.4% Eye Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop of topical anesthesia in one eye
Study: NCT00774982
Drug: Delayed Release 6 mercaptopurine
Normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral tablet, 1 x 40 mg Delayed Release 6MP tablet, single-dose
Study: NCT00774982
Drug: 6 Mercaptopurine
Normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Tablet, 2 x 50 mg 6MP Reference, single-dose
Study: NCT02575703
Drug: [¹⁴C]-LY3023414
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3023414 in solution containing approximately 100 microCi \[¹⁴C\]-LY3023414
Study: NCT03534648
Drug: PF-06865571 administered Day 1-14
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06865571 administered Q12hr on Day 7-14
Study: NCT03534648
Drug: PF-05221304 administered Day 1-14
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-05221304 administered Q12hr on Days 1-14
Study: NCT00193505
Drug: 90Y Zevalin
Normalized name: Zevalin KIT
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04052737
Drug: PMZ-1620 (sovateltide) along with standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in Alzheimer's disease patients.
Study: NCT01607892
Drug: KPT-330
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00036790
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03792009
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: The paracervical injection with 10 mL of normal saline was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
Study: NCT01877655
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection
Study: NCT04083495
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300 mg/m\^2 administered IV for 3 days for lymphodepletion 2-14 days prior to second cell infusion and 2-14 days prior to the first cell infusion for subjects who have previously had hypersensitivity to bendamustine
Study: NCT01901328
Drug: CB-5945
Normalized name: BroveX CB
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01901328
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03047330
Drug: Estradiol withdrawal
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one injection of open-label intramuscular dose of leuprolide (3.75-mg depot), a gonadotropin-releasing hormone agonist that rapidly suppresses estradiol and temporarily achieves ovarian suppression.
Study: NCT02258412
Drug: hand antiseptic with CHG and alcohol
Normalized name: CHG Teat Dip
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCWs will be randomized to use one product on one day and the other product on another day at least 3 days apart. Each product will be applied using 1 pump from its dispenser and rubbed over the hands until dry. Gloves will be worn while the HCW is in the patient room. Upon exit from the room, HCW will washoout with that same product. One imprint will be made of the non-dominant hand onto media containing neutralizers. That hand will be gloved with a white cotton glove. The HCW will work in the common areas with timing recorded. Upon leaving the common area, the dominant ungloved hand will be imprinted onto a fresh media plate containing neutralizers.
Study: NCT02258412
Drug: Alcohol hand sanitizer foam
Normalized name: BENZETHONIUM CHLORIDE 2.5 g in 1 L TOPICAL LIQUID [Sierra Soft Non-Alcohol Hand Sanitizer Foam]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol foam hand sanitizer applied with 1 pump into hands, spread over hands up to the wrist and rubbed until dry. Foam will be applied twice approximately 15-30 minutes apart on one day
Study: NCT01689038
Drug: F17464
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose
Study: NCT00295945
Drug: fentanyl citrate
Normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02283814
Drug: BIA 2-093
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00671281
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, Oral form, three times a day, 3 days before/day of/6 days after surgery
Study: NCT05751525
Drug: Sulfonylurea
Normalized name: Sulfonylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenlclamide / glyburide
Study: NCT04285528
Drug: General anesthetia Fentanyl and Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients were anesthetized using Fentanyl (2 mcg per kg) and Propofol (1-2 mg per kg). Proper classic laryngeal mask airway was inserted afterwards.
Study: NCT01149200
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo as enteric-coated oral hard gelatin capsule, administered twice daily
Study: NCT00520026
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no